FIELD: biology, genetic engineering.
SUBSTANCE: invention concerns molecular biology and genetic engineering. Invention claims synthetic DNA molecule encoding HPV31 L1 protein, virus-like HPV31 particles, vaccine and pharmaceutical composition including virus-like HPV31 particles.
EFFECT: papilloma virus therapy.
17 cl, 6 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
OPTIMISED EXPRESSION LI HPV45 IN YEAST | 2004 |
|
RU2360001C2 |
OPTIMISED EXPRESSION OF HPV 58 L1 IN YEAST | 2004 |
|
RU2370538C2 |
OPTIMISED EXPRESSION OF HPV 52 L1 IN YEAST | 2005 |
|
RU2373219C2 |
VACCINE COMPOSITION APPLICABLE IN HPV AND HEPATITIS VIRUS INFECTIONS, AND METHOD FOR PREPARING IT | 2009 |
|
RU2509570C2 |
RECOMBINANT VACCINE FOR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION AND METHOD OF ITS PREPARATION | 2014 |
|
RU2546243C1 |
METHOD OF OBTAINING A RECOMBINANT VACCINE FOR PREVENTION OF HUMANPAPILLOMA VIRUS INFECTION, RECOMBINANT VACCINE | 2018 |
|
RU2681174C1 |
GENES CODING MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMA VIRUS, AND USING THEM | 2008 |
|
RU2494106C2 |
PAPILLOMA VIRAL VACCINES | 1995 |
|
RU2206608C2 |
PAPILLOMAVIRUS E2 POLYPEPTIDES USED FOR VACCINATION | 2008 |
|
RU2482189C2 |
RECOMBINANT STRAIN OF YEAST Hansenula polymorpha - PRODUCER OF MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMAVIRUS OF TYPE 56 | 2014 |
|
RU2546240C1 |
Authors
Dates
2009-05-27—Published
2004-03-19—Filed